Liver Enzyme Dynamics in Metabolic Disorders

Liver enzymes serve as sensitive indicators of hepatic health, reflecting the balance between synthesis, release and clearance under physiological and pathological conditions. Transaminases such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are central to amino acid metabolism, while gamma-glutamyltransferase (GGT) and alkaline phosphatase (ALP) participate in glutathione turnover and bile formation, respectively. In metabolic disorders—non-alcoholic fatty liver disease (NAFLD), type 2 diabetes and metabolic syndrome—altered lipid handling, insulin resistance and chronic oxidative stress drive hepatocellular injury and induce characteristic shifts in enzyme patterns. These dynamics can emerge even in lean individuals, signalling early derangements in glucose handling and β-cell function. Integration of enzyme measurements with anthropometry, bioimpedance, lipid profiling and insulin sensitivity indices enables stratification of patients by disease stage and cardiometabolic risk. Advances in high-throughput lipidomics and longitudinal cohort studies have illuminated how specific enzyme ratios correlate with steatosis severity, hepatic fibrosis and systemic inflammation. Globally, enzyme assays remain affordable and widely accessible tools for screening, guiding lifestyle or pharmacological interventions and monitoring therapeutic response in diverse populations.

Research from Nature Portfolio

Recent studies have shown that the ALT/AST ratio predicts insulin resistance and affects β-cell function in young and middle-aged women, independent of body mass index, highlighting its value in early diabetes risk assessment. In a Bangladeshi adult cohort, elevations in serum GGT closely tracked dyslipidaemia and generalised obesity, underscoring a mechanistic link between lipid overload and hepatic oxidative stress. Population data on abdominal and general obesity have further demonstrated that ALT and GGT independently correlate with central adiposity, supporting their use as non-invasive markers in epidemiological surveys of metabolic dysfunction.

Liver Enzyme Dynamics in Metabolic Disorders publication trend

The graph below shows the total number of articles in liver enzyme dynamics in metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Alanine aminotransferase (ALT): Enzyme involved in amino acid metabolism; elevated levels indicate hepatocellular injury.

Aspartate aminotransferase (AST): Mitochondrial and cytosolic enzyme reflecting liver and cardiac muscle integrity.

Gamma-glutamyltransferase (GGT): Enzyme contributing to antioxidant glutathione homeostasis and a marker of oxidative stress.

Homeostasis model assessment of insulin resistance (HOMA-IR): Calculator of insulin sensitivity derived from fasting glucose and insulin concentrations.

Non-alcoholic fatty liver disease (NAFLD): Spectrum of liver fat accumulation not due to significant alcohol intake, ranging from steatosis to fibrosis.

References

1. Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. Frontiers in Endocrinology (2024).
2. Associations of alanine aminotransferase/aspartate aminotransferase with insulin resistance and β-cell function in women. Scientific Reports (2023).
3. Usefulness of Body Fat and Visceral Fat Determined by Bioimpedanciometry versus Body Mass Index and Waist Circumference in Predicting Elevated Values of Different Risk Scales for Non-Alcoholic Fatty Liver Disease. Nutrients (2024).
4. Metabolic syndrome and transaminases: systematic review and meta-analysis. Diabetology & Metabolic Syndrome (2023).
5. The association between elevated lipid profile and liver enzymes: a study on Bangladeshi adults. Scientific Reports (2022).
6. Assessment of the relationship of serum liver enzymes activity with general and abdominal obesity in an urban Bangladeshi population. Scientific Reports (2021).